Vyleesi Geriatric (65+) Caregiver Administration Guidance

What the FDA Label Actually Says About Geriatric Use

The FDA-approved prescribing information for bremelanotide states plainly that clinical studies did not enroll enough patients aged 65 and older to determine whether they respond differently from younger patients. No geriatric-specific dose adjustment is listed. That absence of data is itself clinically significant and should not be read as a green light.

The label notes that bremelanotide causes transient blood pressure increases in all adults, and that cardiovascular disease is a contraindication. Prescribing information is posted at FDA.gov under NDA 210557. [1]

Why the Data Gap Matters for Patients Over 65

Age-related changes in body composition, renal clearance, and autonomic blood-pressure regulation all influence how bremelanotide behaves in older adults. A 70-year-old woman taking an antihypertensive faces a very different risk profile than a 38-year-old study participant. Caregivers and prescribers should treat the geriatric population as a higher-monitoring cohort, not simply as older versions of the studied population.

The melanocortin system itself changes with age. MC4R density and signaling efficiency shift across the lifespan, which may alter both the therapeutic effect and the side-effect burden of a melanocortin receptor agonist like bremelanotide. Research on age-related melanocortin system changes is reviewed in the NIH literature. [2]

Regulatory Context: RECONNECT Trials

FDA approval rested on two key Phase 3 trials, RECONNECT Study A and Study B, which enrolled premenopausal women with HSDD. Combined, these trials included approximately 1,267 participants. The mean age was in the mid-30s. Patients aged 65 and older were not a defined subgroup in the primary analyses. Full trial data appear in the NEJM correspondence and FDA medical review. [3]

The FDA medical review documents a statistically significant improvement in the co-primary endpoints (desire and distress scores) versus placebo, but the safety analysis did not power a geriatric subgroup. Prescribers extending this drug to patients over 65 are doing so off the studied age range.

Pharmacokinetics in Aging: What Changes and Why It Matters

Bremelanotide has a half-life of approximately 2.7 hours after subcutaneous injection. Peak plasma concentration (Cmax) occurs at roughly 1 hour post-dose. These parameters are detailed in the FDA clinical pharmacology review. [4]

Renal Clearance and Older Adults

Renal function declines roughly 1% per year after age 40 in otherwise healthy adults, according to data summarized by the National Institute on Aging. NIA aging and kidney function data are published here. [5] Bremelanotide's prescribing information states no dose adjustment is needed for mild-to-moderate renal impairment (eGFR 30 to 89 mL/min/1.73 m²), but pharmacokinetic data in severe renal impairment (eGFR <30) are not available.

A 68-year-old woman with an eGFR of 35 falls within the "no adjustment needed" range on paper, yet her drug exposure may still be meaningfully higher than in a 35-year-old woman with an eGFR of 90. Caregivers should confirm the patient's most recent eGFR with her prescriber before starting administration.

Hepatic Metabolism

Bremelanotide is metabolized primarily by non-enzymatic hydrolysis of the amide bond. That pathway is relatively age-stable compared to cytochrome P450-dependent metabolism, which is genuinely reassuring for polypharmacy management in older adults. Metabolic pathway data are reviewed in the FDA pharmacology review at accessdata.fda.gov. [4]

No dose change is required in mild-to-moderate hepatic impairment. Severe hepatic impairment data are absent, consistent with the renal gap.

Drug Interactions in a Polypharmacy Context

Bremelanotide slows gastric emptying transiently. This effect can reduce the absorption rate of co-administered oral medications. Older adults taking narrow-therapeutic-index drugs, such as warfarin, digoxin, or levothyroxine, should not take those medications within 1 hour of a bremelanotide dose. The FDA label drug interaction section outlines this mechanism. [1]

Naltrexone co-administration is an absolute contraindication. Opioid-based analgesics, which are sometimes prescribed in older adults for chronic pain, may have reduced efficacy if taken around the time of bremelanotide dosing because of melanocortin-opioid receptor cross-talk. This interaction is discussed in published pharmacodynamic literature indexed on PubMed. [6]

Cardiovascular Monitoring in Patients Over 65

Bremelanotide's most clinically significant adverse effect is transient blood pressure elevation. In the RECONNECT trials, the mean systolic increase was +6 mmHg and the mean diastolic increase was +3 mmHg, with peak effect at approximately 4 hours and return to baseline by 12 hours. These hemodynamic data appear in the published FDA label. [1]

Why Older Adults Face Greater Hemodynamic Risk

Arterial stiffness increases with age. Pulse wave velocity rises, baroreceptor sensitivity declines, and the cardiovascular system's ability to buffer an acute blood pressure surge diminishes. Age-related arterial stiffness mechanisms are reviewed in a widely cited paper indexed in PubMed. [7] A +6 mmHg mean systolic rise that is well-tolerated at age 38 may produce symptomatic hypertension in a 72-year-old woman already at a systolic of 138 mmHg.

The FDA label requires measurement of baseline blood pressure before prescribing and contraindicates use in patients with known cardiovascular disease, which the label defines to include uncontrolled hypertension. The American Heart Association defines uncontrolled hypertension as blood pressure consistently above 130/80 mmHg in adults. AHA hypertension guidelines are accessible at ahajournals.org. [8]

Pre-Dose Caregiver Blood Pressure Protocol

Caregivers administering bremelanotide to patients aged 65 and older should follow this sequence:

1. Measure blood pressure with a validated cuff 10 minutes before injection.
2. If systolic is above 130 mmHg or diastolic is above 80 mmHg, hold the dose and contact the prescriber.
3. Document the reading and the time in a medication log.
4. After injection, keep the patient seated or reclining for at least 30 minutes.
5. Measure blood pressure again at 1 hour and at 4 hours post-dose on the first three administrations to establish a personal response baseline.

This protocol is not explicitly stated in the current FDA label but is consistent with the cardiovascular monitoring principles recommended in geriatric pharmacology literature. Geriatric pharmacology monitoring frameworks are reviewed in published NIH-indexed literature. [9]

Injection Technique for Caregiver Administration

The bremelanotide auto-injector delivers a fixed 1.75 mg dose subcutaneously. Approved sites are the abdomen, thigh, and upper arm (lateral aspect). Device and injection instructions are detailed in the FDA patient labeling section of NDA 210557. [1]

Site Selection in Older Adults

Subcutaneous tissue volume and distribution change with age. Fat redistribution away from the limbs and toward the trunk means the upper arm may have less subcutaneous depth in frail older women, increasing the risk of inadvertent intramuscular injection at that site. The abdomen, at least 2 inches from the navel, generally offers the most reliable subcutaneous depth in this population.

Skin fragility is a real concern in patients over 70, particularly those on chronic corticosteroids or with a history of connective tissue disorders. Inspect each site before use. Do not inject into bruised, reddened, or indurated skin.

Rotation Schedule

Rotate among all three sites across consecutive doses. A simple log, whether paper-based or phone-based, prevents repeated use of the same site, which can cause lipodystrophy over time. The same rotation principles apply here as in insulin therapy for type 2 diabetes, where site rotation guidance has been studied extensively. Subcutaneous injection site rotation evidence is reviewed in diabetes care literature on PubMed. [10]

Step-by-Step Caregiver Injection Procedure

1. Wash hands for 20 seconds with soap and water.
2. Remove the auto-injector from the refrigerator 15 minutes before use; room-temperature injection reduces discomfort.
3. Select the site according to the rotation log.
4. Clean the site with an alcohol swab and allow it to dry completely (approximately 30 seconds).
5. Remove the auto-injector cap. Do not touch the needle end.
6. Press the device firmly and straight against the skin. Press the activation button and hold for 5 seconds.
7. Lift the device straight away. The needle guard retracts automatically.
8. Apply gentle pressure with a dry gauze pad. Do not rub.
9. Dispose of the used auto-injector in a sharps container immediately.
10. Document the time, site, lot number, and the patient's pre-dose blood pressure in the medication log.

Managing Nausea: The Most Common Adverse Effect in Older Adults

Nausea occurred in approximately 40% of participants in the RECONNECT program and was the adverse event most commonly causing discontinuation. RECONNECT adverse event data are reported in the FDA medical review. [3] In older adults, nausea poses additional risks beyond discomfort, including aspiration risk, dehydration, and falls during an episode of acute nausea-related unsteadiness.

Antiemetic Pre-Treatment Options

The prescribing information recommends ondansetron 4 mg taken approximately 30 minutes before bremelanotide if nausea is anticipated or has occurred with prior doses. For patients aged 65 and older, prescribers should weigh the QTc-prolonging potential of ondansetron before recommending it routinely. FDA drug safety communication on ondansetron and QT prolongation is posted at fda.gov. [11] A patient already taking a QT-prolonging antidepressant faces additive risk.

Ginger supplementation (250 mg capsule, taken 30 minutes before dosing) has a reasonable evidence base for chemotherapy-induced nausea and is substantially safer in terms of cardiac risk. Ginger antiemetic evidence is reviewed in a Cochrane-adjacent systematic review indexed on PubMed. [12]

Post-Dose Nausea Management

Keep the patient seated, not supine, for at least 30 minutes after injection. Nausea-related vomiting in a supine older adult carries aspiration risk. Offer small sips of clear fluid. Avoid solid food for 1 hour post-dose if nausea is present.

Flushing, Hyperpigmentation, and Skin Considerations

Flushing occurred in roughly 20% of RECONNECT participants and hyperpigmentation (particularly of the face, gums, and breasts) developed in some patients with prolonged use. These dermatological findings are documented in the FDA label. [1]

Hyperpigmentation Risk and Fitzpatrick Scale

Patients with darker skin tones (Fitzpatrick types IV, VI) showed higher rates of hyperpigmentation in post-marketing surveillance. This effect appears to be dose-cumulative. Caregivers should photograph baseline skin in affected areas at the start of therapy and re-examine monthly. Any new or expanding hyperpigmentation should be reported to the prescriber, who may choose to discontinue therapy. Melanocortin receptor agonism and pigmentation are reviewed in published dermatology literature indexed on PubMed. [13]

Contraindications Particularly Relevant to the 65+ Population

Several absolute contraindications in the bremelanotide label map directly onto conditions that are substantially more prevalent in patients over 65.

Cardiovascular Disease

The label contraindicates use in patients with known cardiovascular disease. Cardiovascular disease prevalence in women aged 65 to 74 in the United States is approximately 19%, rising to 32% in women aged 75 to 84, based on American Heart Association statistics. AHA 2024 Heart Disease and Stroke Statistics are published at ahajournals.org. [14] Caregivers must verify that a formal cardiovascular assessment has been completed and documented before beginning administration.

Naltrexone Use

Naltrexone is used in older adults for alcohol use disorder and opioid use disorder at increasing rates. Co-administration with bremelanotide is contraindicated because naltrexone blocks the melanocortin opioid receptor pathways through which bremelanotide exerts part of its effect, rendering the drug ineffective and creating unpredictable hemodynamic responses. Melanocortin and opioid receptor interaction pharmacology is reviewed in NIH-indexed literature. [6]

Uncontrolled Hypertension

Blood pressure control should be confirmed within 30 days before initiating bremelanotide in any patient over 65. The prescribing physician should document a recent blood pressure reading and confirm it is below 130/80 mmHg. JNC hypertension thresholds and the ACC/AHA 2017 guidelines are published at ahajournals.org. [8]

Practical Caregiver Communication and Documentation

Caregivers administering Vyleesi to a geriatric patient carry real clinical responsibility. The following documentation practices reduce risk and support continuity of care.

Medication Log Requirements

A written or electronic log should capture, for each dose: the date and time of injection, the injection site used, the pre-dose blood pressure reading, any adverse effects observed, and the time those effects resolved. This log should be shared with the prescribing clinician at every follow-up visit.

The American Geriatrics Society's Beers Criteria, updated in 2023, does not specifically list bremelanotide as a drug to avoid in older adults, but the general principle of heightened monitoring for drugs that affect blood pressure and have limited geriatric trial data applies fully here. The 2023 AGS Beers Criteria update is indexed on PubMed. [15]

When to Withhold a Dose and Call the Prescriber

Caregivers should withhold the dose and contact the prescribing clinician if any of the following are present on the day of planned administration:

• Systolic blood pressure above 130 mmHg or diastolic above 80 mmHg on two readings taken 5 minutes apart.
• Active nausea or vomiting from any cause.
• A new or changed cardiac medication added within the past 7 days.
• Any new chest pain, palpitations, or shortness of breath in the preceding 48 hours.
• Skin at all approved injection sites shows active bruising, infection, or induration.

The prescribing information states that patients and caregivers should be instructed to seek immediate medical attention for severe or persistent increases in blood pressure. FDA label emergency instructions are in section 5.1 of the full prescribing information. [1]

Communication With the Prescriber

The Endocrine Society's clinical practice guidelines on sexual dysfunction in women recommend reassessment at 8 weeks after starting any pharmacological treatment for HSDD, with particular attention to adverse effects and treatment response. Endocrine Society guidelines on female sexual dysfunction are published at academic.oup.com. [16] Caregivers should schedule this follow-up appointment at the time the first prescription is filled, not after problems arise.

Storage and Handling for Home Caregiver Settings

Bremelanotide auto-injectors must be refrigerated at 36 to 46°F (2 to 8°C). They may be stored at room temperature, below 77°F (25°C), for a maximum of 30 days. Storage requirements are confirmed in the FDA label. [1] Do not freeze the device; freezing damages the auto-injector mechanism and may alter drug stability.

In households where a caregiver manages multiple injectable medications, label each refrigerator shelf clearly to prevent mix-ups. Vyleesi packaging is distinct, but in a household also managing insulin, GLP-1 receptor agonists, or B12 injections, the risk of selection error is real.

Expired auto-injectors must be returned to a pharmacy take-back program or disposed of in a sharps container. Do not discard in household trash.